Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Gains from Investment Securities: 2013-2025

Historic Gains from Investment Securities for KalVista Pharmaceuticals (KALV) over the last 11 years, with Apr 2025 value amounting to $1.6 million.

  • KalVista Pharmaceuticals' Gains from Investment Securities rose 89.23% to $369,000 in Q2 2025 from the same period last year, while for Apr 2025 it was $1.5 million, marking a year-over-year increase of 15.47%. This contributed to the annual value of $1.6 million for FY2025, which is 17.81% up from last year.
  • KalVista Pharmaceuticals' Gains from Investment Securities amounted to $1.6 million in FY2025, which was up 17.81% from $1.3 million recorded in FY2024.
  • KalVista Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $4.8 million during FY2021, with a 5-year trough of $1.2 million in FY2023.
  • In the last 3 years, KalVista Pharmaceuticals' Gains from Investment Securities had a median value of $1.3 million in 2024 and averaged $1.4 million.
  • Per our database at Business Quant, KalVista Pharmaceuticals' Gains from Investment Securities surged by 1,448.22% in 2021 and then crashed by 62.57% in 2023.
  • Yearly analysis of 5 years shows KalVista Pharmaceuticals' Gains from Investment Securities stood at $4.8 million in 2021, then plummeted by 33.42% to $3.2 million in 2022, then slumped by 62.57% to $1.2 million in 2023, then climbed by 11.16% to $1.3 million in 2024, then grew by 17.81% to $1.6 million in 2025.